Chemistry:Maxacalcitol

From HandWiki

Maxacalcitol (trade name Oxarol) is a vitamin D3 analog and vitamin D receptor activator (VDRA).[1] As a pharmaceutical drug, it is used as an injection to treat secondary hyperparathyroidism resulting from hemodialysis and as a topical ointment for psoriasis.[2]

It was approved for use in Japan in 2010[3] and in Taiwan in 2018.[4]

References

  1. ↑ "Clinical uses of 22-oxacalcitriol". Current Vascular Pharmacology 12 (2): 324–328. March 2014. doi:10.2174/15701611113119990023. PMID 23713875. 
  2. ↑ "Maxacalcitol". Inxight Drugs. National Center for Advancing Translational Sciences, U.S. National Institutes of Health. https://drugs.ncats.io/drug/N2UJM5NBF6. 
  3. ↑ "Maxacalcitol". New Drug Approvals in Japan. Kyoto Encyclopedia of Genes and Genomes. https://www.genome.jp/kegg/drug/br08318.html?id=D01098. 
  4. ↑ "Maxacalcitol Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Secondary Hyperparathyroidism in Patients Receiving Maintenance Hemodialysis". Drug Research 72 (1): 23–33. January 2022. doi:10.1055/a-1581-7609. PMID 34488237. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Maxacalcitol&oldid=4033673"